- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07664111
Ketogenic Dietary Intervention in Men With Mild-to-Moderate COPD (COPDKETO)
Effects of an 8-Week Ketogenic Dietary Intervention on Pulmonary Function, Systemic Inflammation, Body Composition, and Functional Exercise Capacity in Men With Mild-to-Moderate Chronic Obstructive Pulmonary Disease: A Pilot Randomized Controlled Trial
Chronic obstructive pulmonary disease (COPD) is associated with persistent airflow limitation, systemic inflammation, reduced exercise capacity, and unfavorable changes in body composition. Nutritional interventions may represent a complementary strategy to improve clinical outcomes in individuals with COPD.
This pilot randomized controlled trial evaluates the feasibility, safety, and preliminary effectiveness of an 8-week ketogenic dietary intervention in men with mild-to-moderate COPD. Participants are randomly assigned to either a supervised ketogenic diet or a control group receiving standard dietary advice. The ketogenic diet restricts carbohydrate intake and promotes nutritional ketosis, which is monitored using blood beta-hydroxybutyrate measurements.
The primary outcome is change in the FEV1/FVC ratio. Secondary outcomes include systemic inflammation assessed by C-reactive protein (CRP), phase angle measured by bioelectrical impedance analysis, functional exercise capacity assessed by the 6-minute walk test, estimated aerobic capacity, body composition, and selected biochemical safety markers. The study aims to provide preliminary evidence regarding whether a ketogenic dietary approach may improve inflammatory status, functional capacity, and physiological outcomes in individuals with COPD.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation, chronic inflammation, exercise intolerance, and alterations in body composition. In addition to pulmonary impairment, systemic manifestations such as increased inflammatory burden, skeletal muscle dysfunction, and adverse metabolic changes contribute substantially to morbidity and reduced quality of life. Nutritional interventions have therefore emerged as potential adjunctive strategies in COPD management.
Ketogenic diets are characterized by marked carbohydrate restriction, moderate protein intake, and increased dietary fat consumption, resulting in nutritional ketosis. Potential mechanisms relevant to COPD include reductions in systemic inflammation, changes in substrate utilization, reductions in adiposity, and alterations in respiratory gas exchange. However, randomized controlled studies investigating ketogenic dietary interventions in COPD remain limited.
This study is an 8-week, single-center, parallel-group pilot randomized controlled trial conducted in clinically stable men with GOLD stage I-II COPD. Participants are randomly allocated in a 1:1 ratio to either a ketogenic dietary intervention or a control group receiving standard dietary advice. The ketogenic diet is individually prescribed by a dietitian and aims to provide approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day.
Nutritional ketosis is monitored using capillary beta-hydroxybutyrate measurements obtained throughout the intervention period. Pulmonary function is assessed using spirometry. Body composition and phase angle are measured using multifrequency bioelectrical impedance analysis. Functional exercise capacity is evaluated using the 6-minute walk test, and estimated aerobic capacity is derived from walking performance. Blood samples are collected to assess inflammatory and safety-related biomarkers, including C-reactive protein, lipid parameters, alanine aminotransferase, and creatinine.
The primary objective is to determine whether an 8-week ketogenic dietary intervention improves FEV1/FVC compared with standard dietary advice. Secondary objectives are to evaluate effects on systemic inflammation, phase angle, exercise capacity, body composition, and biochemical safety outcomes. As a pilot trial, the study is designed to generate effect-size estimates, assess feasibility and adherence, and inform the design of future larger multicenter randomized controlled trials.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Ağrı, Turkiet (Türkiye)
- Ağrı İbrahim Çeçen University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Male sex
- Age between 40 and 75 years
- Clinically stable chronic obstructive pulmonary disease (COPD)
- GOLD stage I or II COPD
- No acute COPD exacerbation within the previous 3 months
- Stable pharmacological treatment for at least 4 weeks before enrollment
- Ability to complete study assessments and comply with dietary instructions
- Provision of written informed consent
Exclusion Criteria:
- GOLD stage III or IV COPD
- Uncontrolled cardiovascular disease
- Chronic kidney disease
- Severe hepatic dysfunction
- Active malignancy
- Insulin-dependent diabetes mellitus
- Participation in another dietary intervention program within the previous 3 months
- Inability to complete study assessments
- Contraindications to dietary carbohydrate restriction
- Refusal or inability to provide informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ketogenic Diet
Participants received an individualized ketogenic dietary intervention for 8 weeks.
The dietary prescription provided approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day.
Nutritional ketosis was monitored using blood beta-hydroxybutyrate measurements.
|
Participants received an individualized ketogenic dietary intervention for 8 weeks.
The dietary prescription provided approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day.
Nutritional ketosis was monitored using blood beta-hydroxybutyrate measurements throughout the intervention period.
|
|
Aktiv komparator: Standard Dietary Advice
Participants received standard dietary recommendations for chronic obstructive pulmonary disease and were instructed to maintain their habitual dietary patterns throughout the 8-week study period.
|
Participants received standard dietary recommendations for chronic obstructive pulmonary disease and were instructed to maintain their habitual dietary patterns during the 8-week study period.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
FEV1/FVC Ratio
Tidsram: Change in the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), assessed by spirometry after 8 weeks of intervention.
|
Baseline and Week 8
|
Change in the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), assessed by spirometry after 8 weeks of intervention.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
C-Reactive Protein (CRP)
Tidsram: Baseline and Week 8
|
Serum C-reactive protein concentration (mg/L) measured as a marker of systemic inflammation.
|
Baseline and Week 8
|
|
Phase Angle
Tidsram: Baseline and Week 8
|
Change in phase angle measured by multifrequency bioelectrical impedance analysis.
|
Baseline and Week 8
|
|
6-Minute Walk Distance
Tidsram: Baseline and Week 8
|
Change in functional exercise capacity assessed by the 6-minute walk test.
|
Baseline and Week 8
|
|
Body Mass Index
Tidsram: Baseline and Week 8
|
Baseline and Week 8Change in body mass index calculated as weight divided by height squared.
|
Baseline and Week 8
|
|
Fat Mass
Tidsram: Baseline and Week 8
|
Baseline and Week 8Change in body fat mass measured by bioelectrical impedance analysis.
|
Baseline and Week 8
|
|
Estimated VO2max
Tidsram: Baseline and Week 8
|
Baseline and Week 8Change in estimated maximal oxygen uptake derived from 6-minute walk performance.
|
Baseline and Week 8
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Dursun Alper YILMAZ, Ağrı İbrahim Çeçen Üniversitesi
Publikationer och användbara länkar
Allmänna publikationer
- Ji J, Fotros D, Sohouli MH, Velu P, Fatahi S, Liu Y. The effect of a ketogenic diet on inflammation-related markers: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2025 Jan 1;83(1):40-58. doi: 10.1093/nutrit/nuad175.
- Norwitz NG, Winwood R, Stubbs BJ, D'Agostino DP, Barnes PJ. Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease. Front Med (Lausanne). 2021 Jul 29;8:699427. doi: 10.3389/fmed.2021.699427. eCollection 2021.
- Maddocks M, Kon SS, Jones SE, Canavan JL, Nolan CM, Higginson IJ, Gao W, Polkey MI, Man WD. Bioelectrical impedance phase angle relates to function, disease severity and prognosis in stable chronic obstructive pulmonary disease. Clin Nutr. 2015 Dec;34(6):1245-50. doi: 10.1016/j.clnu.2014.12.020. Epub 2015 Jan 7.
- Collins PF, Yang IA, Chang YC, Vaughan A. Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. J Thorac Dis. 2019 Oct;11(Suppl 17):S2230-S2237. doi: 10.21037/jtd.2019.10.41.
- Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447-458. doi: 10.1016/S2213-2600(21)00511-7. Epub 2022 Mar 10.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Luftvägssjukdomar
- Lungsjukdomar
- Lungsjukdomar, obstruktiv
- Patologiska tillstånd, tecken och symtom
- Lungsjukdom, kronisk obstruktiv
- Terapeutik
- Diet, mat och näring
- Fysiologiska fenomen
- Näringsfysiologiska fenomen
- Dieterapi
- Näringsterapi
- Diet
- Diet, kolhydratbegränsad
- Diet, ketogen
Andra studie-ID-nummer
- AICU-COPD-KETO-RCT-2026
- SABF.25.003 (Annat bidrag/finansieringsnummer: Ağrı İbrahim Çeçen University Scientific Research Projects Unit (BAP))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .